Treatment Outcomes of Primary vs. Referred Patients with Multiple Myeloma Receiving Talquetamab or Teclistamab

被引：0
|
作者：
Fries, Gina [1 ]
Alshlah, Ali [1 ]
Baran, Andrea [1 ]
Lipe, Brea [2 ]
机构：
[1] Univ Rochester, Med Ctr, Rochester, NY USA
[2] UR Med, Dept Med, Rochester, NY USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-119
引用
收藏
页码：S110 / S110
页数：1
相关论文
共 50 条
  • [1] Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma
    Cohen, Yael C.
    Magen, Hila
    Gatt, Moshe
    Sebag, Michael
    Kim, Kihyun
    Min, Chang-Ki
    Ocio, Enrique M.
    Yoon, Sung-Soo
    Chu, Michael P.
    Rodriguez-Otero, Paula
    Avivi, Irit
    Quijano Carde, Natalia A.
    Kumar, Ashwini
    Krevvata, Maria
    Peterson, Michelle R.
    Di Scala, Lilla
    Scott, Emma
    Hilder, Brandi
    Vanak, Jill
    Banerjee, Arnob
    Oriol, Albert
    Morillo, Daniel
    Mateos, Maria-Victoria
    NEW ENGLAND JOURNAL OF MEDICINE, 2025, 392 (02): : 138 - 149
  • [2] Prevalent Treatment Patterns of Teclistamab and Talquetamab for Multiple Myeloma (MM): Experience from 609 Patients
    Chunara, Farheen
    Shah, Mansi R.
    Shah, Nishi
    Kent, Jessica
    Mohyuddin, Ghulam Rehman
    Radhakrishnan, Sabarinath, V
    Kaur, Gurbakhash
    Chakraborty, Rajshekhar
    Rasche, Leo
    Schinke, Carolina
    D'Souza, Anita
    Szabo, Aniko
    Mohan, Meera
    BLOOD, 2024, 144 : 2395 - 2395
  • [3] Evaluation of Clinical Outcomes and Toxicities in Multiple Myeloma Patients Receiving Commercial Talquetamab
    Lu, Rebecca
    Chen, Jessica
    Ow, Karla
    Hildebrandt, Michelle
    Huen, Auris
    Cardoso, Richard
    Chambers, Mark
    Abreu, Michelly
    Cuellar, Elizabeth
    Ighovoyivwi, Efe
    Knight, Sarah
    Santiago, Minifrida
    Savoie, Cecilia
    Varghese, Jaimole
    Zachariah, Annie
    Becnel, Melody
    Gaballa, Mahmoud
    Orlowski, Robert
    Patel, Krina
    Pasvolsky, Oren
    Thomas, Sheeba
    Ye, Jing Christine
    Weber, Donna
    Lee, Hans
    Richards, Tiffany
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S281 - S281
  • [4] Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma
    Girgis, Suzette
    Lin, Shun Xin Wang
    Pillarisetti, Kodandaram
    Verona, Raluca
    Vieyra, Diego
    Casneuf, Tineke
    Fink, Damien
    Miao, Xin
    Chen, Yang
    Stephenson, Tara
    Banerjee, Arnob
    Hilder, Brandi W.
    Russell, Jeffery
    Infante, Jeffrey
    Elsayed, Yusri
    Smit, Jennifer
    Goldberg, Jenna D.
    BLOOD ADVANCES, 2023, 7 (04) : 644 - 648
  • [5] Use of Baseline Inflammatory Markers to Predict Toxicities Among Relapsed/Refractory Multiple Myeloma Patients Receiving Ambulatory Teclistamab and Talquetamab
    Tabbara, Nadeem
    Singel, Michael
    Allen, Natalie
    Shedeck, Audra
    Mooney, Kathy
    Campion, Kathryn
    Raymond, Callan
    Sabirzhanova, Inna
    Anderson, Karen
    Waheed, Sarah
    Huff, Carol Ann
    Ali, Syed Abbas
    Gocke, Christian B.
    Imus, Philip
    BLOOD, 2024, 144 : 7232 - 7233
  • [6] Real-World Outcomes of Patients with Relapsed/Refractory Multiple Myeloma Treated with Teclistamab and Talquetamab; A Multicenter Analysis from the Greek Myeloma Study Group
    Ntanasis-Stathopoulos, Ioannis
    Katodrytou, Eirini
    Hatjiharissi, Evdoxia
    Spanoudakis, Emmanouil
    Douka, Vasiliki
    Fotiou, Despina
    Labropoulou, Vasiliki
    Dalampira, Dimitra
    Spiliopoulou, Vasiliki
    Papadopoulou, Theodosia
    Christoulas, Dimitrios
    Malandrakis, Panagiotis
    Bouchla, Anthi
    Pappa, Vasiliki
    Kastritis, Efstathios
    Terpos, Evangelos
    Dimopoulos, Meletios
    Gavriatopoulou, Maria
    BLOOD, 2024, 144 : 6988 - 6990
  • [7] Teclistamab for the treatment of multiple myeloma
    Sester, Lilli Sophie
    Goldschmidt, Hartmut
    Nitschmann, Sirka
    INNERE MEDIZIN, 2023, 64 (02): : 214 - 216
  • [8] Elranatamab vs. teclistamab: battle of the BCMA bispecifics in relapsed/refractory multiple myeloma
    Moore, Donald C.
    Granger, Katelynn
    Hill, Hailey
    Karabinos, Allison
    Davis, James A.
    EXPERT REVIEW OF HEMATOLOGY, 2024, 17 (06) : 197 - 200
  • [9] Modulation of soluble B-cell maturation antigen levels in patients with relapsed and/or refractory multiple myeloma after treatment with teclistamab and talquetamab
    Girgis, Suzette
    Lin, Shun Xin Wang
    Pillarisetti, Kodandaram
    Verona, Raluca
    Vieyra, Diego
    Casneuf, Tineke
    Fink, Damien
    Miao, Xin
    Chen, Yang
    Stephenson, Tara
    Banerjee, Arnob
    Hilder, Brandi
    Russell, Jeffery
    Smit, Jennifer
    Goldberg, Jenna
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S39 - S40
  • [10] Inpatient vs Outpatient Use of Teclistamab in Multiple Myeloma
    Chari, Ajai
    Callander, Natalie
    Pianko, Matthew James
    Schmidt, Timothy
    Landgren, C. Ola
    Costello, Caitlin
    ONCOLOGY-NEW YORK, 2024, 38 (02):
12345